A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa

Trial Profile

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 04 Aug 2017 According to a Sage Therapeutics Media Release, Part B study has been initiated.
    • 09 May 2017 According to a Sage Therapeutics Media Release, Part B study is expected to be initiated in the first half of 2017 with top-line results anticipated in the second half of 2017.
    • 09 May 2017 Topline results (n=12) from the Part A open-label portion ofthis trial published in a Sage Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top